Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Zai Lab Limited

< Previous 1 2 3 Next >
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Participation in Investor Conferences in September 2025
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Establishes Oncology Scientific Advisory Board
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Participation in Investor Conferences in June 2025
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Participation in Investor Conferences in March 2025
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
From Zai Lab Limited
Via Business Wire
Tickers VRTX ZLAB
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.